EUVIMEDOpdag EUVIMED
ÜbersichtsarbeitOpen access · CC BY 4.0

Phage to ESKAPE: Personalizing Therapy for MDR Infections—A Comprehensive Clinical Review

Andrea Marino iD, Stefano Stracquadanio iD, Federica Cosentino iD, Alberto Enrico Maraolo iD, Agnese Colpani iD, Andrea De Vito iD, Nicholas Geremia iD, Alice Nicolosi iD, Alessandra Oliva iD, Bruno Cacopardo, Giuseppe Nunnari iD

Pathogens · 2025-10-07 · 14 (10) · 1011

DOI: 10.3390/pathogens14101011 ↗

At a glance

Übersichtsarbeit in Pathogens, published online on 2025-10-07. Written by Andrea Marino and 10 co-authors. Institution: Unit of Infectious Diseases, Department of Clinical and Experimental Medicine, ARNAS Garibaldi Hospital, University of Catania, 95122 Catania, Italy. Major MEDLINE topics: Phage Therapy, Drug Resistance, Multiple, Bacterial, Bacteriophages, Bacterial Infections. Cited 23 times so far (Crossref); 151 references. The full text is freely available (open access, CC BY 4.0).

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

The proliferation of multidrug-resistant (MDR) ESKAPE pathogens—Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter spp.—constitutes a critical global health crisis, rendering conventional antibiotics increasingly ineffective. This comprehensive review evaluates the re-emerging potential of bacteriophage therapy as a personalized treatment for infections caused by these organisms. Phages, being viruses that specifically infect and lyse bacteria, offer significant advantages, including high specificity that spares host microbiota, self-replication at the infection site, and potent activity against biofilms. This paper synthesizes current preclinical and clinical evidence, including compassionate-use cases, for phage therapy against each of the ESKAPE pathogens. While case reports and small studies demonstrate considerable success, particularly in salvage therapy for otherwise untreatable infections, significant challenges remain. These include the narrow host range of phages, the potential for bacterial resistance, unpredictable pharmacokinetic and pharmacodynamic parameters, and a complex, non-harmonized regulatory landscape. The review highlights that phage–antibiotic synergy and the use of phage cocktails are promising strategies to overcome some of these limitations. Future progress in phage therapy will depend on standardized manufacturing, robust clinical trials to establish dosing and efficacy, and the development of adaptive regulatory pathways. Phage therapy is positioned not as a replacement for antibiotics but as a vital adjunctive tool in the armamentarium against MDR infections, heralding a move towards a more personalized approach to infectious disease management.

Subjects

MeSH terms (MEDLINE)

Phage TherapyDrug Resistance, Multiple, BacterialBacteriophagesBacterial InfectionsHumansPrecision MedicineAnti-Bacterial AgentsAcinetobacter baumanniiKlebsiella pneumoniae

Author keywords

ESKAPE pathogensantimicrobial resistance (AMR)bacteriophage therapybiofilmphage–antibiotic synergy

Substances

Anti-Bacterial Agents

Authors and institutions

  • Unit of Infectious Diseases, Department of Clinical and Experimental Medicine, ARNAS Garibaldi Hospital, University of Catania, 95122 Catania, Italy.
  • Department of Medicine and Surgery, "Kore" University of Enna, 94100 Enna, Italy.
  • Section of Infectious Diseases, Department of Clinical Medicine and Surgery, University of Naples "Federico II", 80138 Naples, Italy.
  • Unit of Infectious Diseases, Department of Medicine, Surgery and Pharmacy, University of Sassari, 07100 Sassari, Italy.
  • Unit of Infectious Diseases, Department of Clinical Medicine, Ospedale "dell'Angelo", 30174 Venice, Italy.
  • Section of Microbiology, Department of Biomedical and Biotechnological Sciences, University of Catania, 95123 Catania, Italy.

ORCID profiles: Andrea Marino, Stefano Stracquadanio, Federica Cosentino, Alberto Enrico Maraolo, Agnese Colpani, Andrea De Vito, Nicholas Geremia, Alice Nicolosi, Alessandra Oliva, Giuseppe Nunnari

Cite

APA

Marino, A., Stracquadanio, S., Cosentino, F., Maraolo, A. E., Colpani, A., De Vito, A., Geremia, N., Nicolosi, A., Oliva, A., Cacopardo, B., & Nunnari, G. (2025). Phage to ESKAPE: Personalizing Therapy for MDR Infections—A Comprehensive Clinical Review. Pathogens, 14(10), 1011. https://doi.org/10.3390/pathogens14101011

Vancouver

Marino A, Stracquadanio S, Cosentino F, Maraolo AE, Colpani A, De Vito A, et al. Phage to ESKAPE: Personalizing Therapy for MDR Infections—A Comprehensive Clinical Review. Pathogens. 2025;14(10):1011. doi:10.3390/pathogens14101011

BibTeX
@article{Marino2025,
  author = {Marino, Andrea and Stracquadanio, Stefano and Cosentino, Federica and Maraolo, Alberto Enrico and Colpani, Agnese and De Vito, Andrea and Geremia, Nicholas and Nicolosi, Alice and Oliva, Alessandra and Cacopardo, Bruno and Nunnari, Giuseppe},
  title = {Phage to ESKAPE: Personalizing Therapy for MDR Infections—A Comprehensive Clinical Review},
  journal = {Pathogens},
  year = {2025},
  volume = {14},
  number = {10},
  pages = {1011},
  doi = {10.3390/pathogens14101011}
}
Start for free →